Vor Biopharma Financials - Benzinga

Vor Biopharma Inc

VORNASDAQ

Trade with Public

Trade with Public

$23.07

-0.51-2.18%

At close: Aug 19, 5:00 PM EST

$23.06

-0.52-2.21%

Pre-Market: 7:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Vor Biopharma Financials

Vor Biopharma (VOR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
UPDATE: Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.70) by 14.29 percent. This is a 98.17 percent increase over losses of $(43.80) per share from

Benzinga Newsdesk

PRO
Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.70) by 65.71 percent. This is a 99.54 percent increase over losses of $(251.24) per share from

Benzinga Newsdesk

PRO
Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 85.96 percent increase over losses of $(5.20) per share from the

Benzinga Newsdesk

PRO
Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.63) per share which beat the analyst consensus estimate of $(1.64) by 0.61 percent. This is a 81.48 percent increase over losses of $(8.80) per share from the

Benzinga Newsdesk

PRO
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(3.33) per share which missed the analyst consensus estimate of $(3.25) by 2.37 percent. This is a 58.39 percent increase over losses of $(8.00) per share from the

Benzinga Newsdesk

PRO
Vor Biopharma Q3 EPS $(121.63) May Not Compare To $(3.32) Estimate

Benzinga Newsdesk